In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 569-577

  Gravett, Andrew M ^a   Liu, Wai M ^a   Krishna, Sanjeev ^b   Chan, Wing Chi ^c   Haynes, Richard K ^c   Wilson, Natalie L ^a   Dalgleish, Angus G ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Artemisinin; Artemisone; Cancer; Cell cycle; Combination

Indexed keywords

ARTEMISININ DERIVATIVE; ARTEMISONE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; GEMCITABINE; OXALIPLATIN; THALIDOMIDE; ANTINEOPLASTIC AGENT; ARTEMISININ; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; CELL CYCLE; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; IC 50; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; THALIDOMIDE;

EID: 79953779279     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1355-4     Document Type: Article

References (46)

1. DL Klayman 1985 Qinghaosu (artemisinin): an antimalarial drug from China Science 228 1049 1055 1:CAS:528:DyaL2MXktlWrt7s%3D 10.1126/science.3887571 3887571 (Pubitemid 15227365)
2. J Golenser JH Waknine M Krugliak NH Hunt GE Grau 2006 Current perspectives on the mechanism of action of artemisinins Int J Parasitol 36 1427 1441 1:CAS:528:DC%2BD28Xht1aju7fF 10.1016/j.ijpara.2006.07.011 17005183 (Pubitemid 44751746)
3. S Krishna L Bustamante RK Haynes HM Staines 2008 Artemisinins: their growing importance in medicine Trends Pharmacol Sci 29 520 527 1:CAS:528:DC%2BD1cXhtFOmurjL 10.1016/j.tips.2008.07.004 18752857
4. RK Haynes B Fugmann J Stetter K Rieckmann HD Heilmann HW Chan MK Cheung WL Lam HN Wong SL Croft L Vivas L Rattray L Stewart W Peters BL Robinson MD Edstein B Kotecka DE Kyle B Beckermann M Gerisch M Radtke G Schmuck W Steinke U Wollborn K Schmeer A Romer 2006 Artemisone-a highly active antimalarial drug of the artemisinin class Angew Chem Int Ed Engl 45 2082 2088 1:CAS:528: DC%2BD28Xjt1Ogs7s%3D 10.1002/anie.200503071 16444785 (Pubitemid 44105182)
5. GQ Li K Arnold XB Guo HX Jian LC Fu 1984 Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria Lancet 2 1360 1361 1:STN:280:DyaL2M%2FlvF2qsQ%3D%3D 10.1016/S0140-6736(84)92057-9 6150365 (Pubitemid 15175082)
6. GQ Li XB Guo LC Fu HX Jian XH Wang 1994 Clinical trials of artemisinin and its derivatives in the treatment of malaria in China Trans R Soc Trop Med Hyg 88 Suppl 1 S5 S6 10.1016/0035-9203(94)90460-X 8053027 (Pubitemid 124018813)
7. WHO Guidelines for the treatment of malaria (2006)
8. L Vivas L Rattray LB Stewart BL Robinson B Fugmann RK Haynes W Peters SL Croft 2007 Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo J Antimicrob Chemother 59 658 665 1:CAS:528:DC%2BD2sXltVKgsr0%3D 10.1093/jac/dkl563 17337512 (Pubitemid 47073399)
9. M Ramharter D Burkhardt J Nemeth AA Adegnika PG Kremsner 2006 In vitro activity of artemisone compared with artesunate against Plasmodium falciparum Am J Trop Med Hyg 75 637 639 1:CAS:528:DC%2BD28XhtF2ltbvJ 17038685 (Pubitemid 46941267)
10. J Nagelschmitz B Voith G Wensing A Roemer B Fugmann RK Haynes BM Kotecka KH Rieckmann MD Edstein 2008 First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone Antimicrob Agents Chemother 52 3085 3091 1:CAS:528:DC%2BD1cXhtF2gtrnJ 10.1128/AAC.01585-07 18559649
11. HJ Woerdenbag TA Moskal N Pras TM Malingre FS el-Feraly HH Kampinga AW Konings 1993 Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells J Nat Prod 56 849 856 1:CAS:528:DyaK3sXlslemur4%3D 10.1021/np50096a007 8350087 (Pubitemid 23195612)
12. T Efferth H Dunstan A Sauerbrey H Miyachi CR Chitambar 2001 The anti-malarial artesunate is also active against cancer Int J Oncol 18 767 773 1:CAS:528:DC%2BD3MXivVWqtbw%3D 11251172
13. HH Chen HJ Zhou X Fang 2003 Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro Pharmacol Res 48 231 236 1:CAS:528:DC%2BD3sXltl2hu7c%3D 10.1016/S1043-6618(03)00107-5 12860439 (Pubitemid 36818928)
14. I Nakase H Lai NP Singh T Sasaki 2008 Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation Int J Pharm 354 28 33 1:CAS:528:DC%2BD1cXjsFOqurs%3D 10.1016/j.ijpharm.2007.09. 003 17942255 (Pubitemid 351400327)
15. LN Li HD Zhang SJ Yuan ZY Tian L Wang ZX Sun 2007 Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway Int J Cancer 121 1360 1365 1:CAS:528: DC%2BD2sXhtVSmtL%2FK 10.1002/ijc.22804 17520675 (Pubitemid 47293806)
16. H Chen B Sun S Pan H Jiang X Sun 2009 Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo Anticancer Drugs 20 131 140 10.1097/CAD.0b013e3283212ade 19209030
17. TG Berger D Dieckmann T Efferth ES Schultz JO Funk A Baur G Schuler 2005 Artesunate in the treatment of metastatic uveal melanoma-first experiences Oncol Rep 14 1599 1603 1:CAS:528:DC%2BD2MXhtlGns7%2FL 16273263
18. NP Singh VK Panwar 2006 Case report of a pituitary macroadenoma treated with artemether Integr Cancer Ther 5 391 394 10.1177/1534735406295311 17101767 (Pubitemid 44722000)
19. ZY Zhang SQ Yu LY Miao XY Huang XP Zhang YP Zhu XH Xia DQ Li 2008 Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial Zhong Xi Yi Jie He Xue Bao 6 134 138 1:CAS:528:DC%2BD1cXjtlygsro%3D 10.3736/jcim20080206 18241646 (Pubitemid 351255891)
20. J Hou D Wang R Zhang H Wang 2008 Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action Clin Cancer Res 14 5519 5530 1:CAS:528:DC%2BD1cXhtVKmsbnE 10.1158/1078-0432.CCR-08-0197 18765544
21. NP Singh HC Lai 2004 Artemisinin induces apoptosis in human cancer cells Anticancer Res 24 2277 2280 1:CAS:528:DC%2BD2cXot1Cgur8%3D 15330172 (Pubitemid 39166306)
22. HJ Zhou Z Wang A Li 2008 Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression Anticancer Drugs 19 247 255 10.1097/CAD.0b013e3282f3f152 18510170
23. HH Chen HJ Zhou WQ Wang GD Wu 2004 Antimalarial dihydroartemisinin also inhibits angiogenesis Cancer Chemother Pharmacol 53 423 432 1:CAS:528: DC%2BD2cXivVCltbc%3D 10.1007/s00280-003-0751-4 15132130 (Pubitemid 38553665)
24. M Wartenberg S Wolf P Budde F Grunheck H Acker J Hescheler G Wartenberg H Sauer 2003 The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies Lab Invest 83 1647 1655 1:CAS:528:DC%2BD3sXoslyksbg%3D 10.1097/01.LAB.0000098424.38003.FF 14615418 (Pubitemid 37421105)
25. E Buommino A Baroni N Canozo M Petrazzuolo R Nicoletti A Vozza MA Tufano 2009 Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production Invest New Drugs 27 412 418 1:CAS:528:DC%2BD1MXhtFent77E 10.1007/s10637-008-9188-2 18956140
26. IR Ribeiro P Olliaro 1998 Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials Med Trop (Mars.) 58 50 53 1:STN:280:DyaK1M3ivFelug%3D%3D (Pubitemid 128707818)
27. T Gordi EI Lepist 2004 Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 147 99 107 1:CAS:528: DC%2BD2cXmvF2hsQ%3D%3D 10.1016/j.toxlet.2003.12.009 14757313 (Pubitemid 38130178)
28. M Adjuik A Babiker P Garner P Olliaro W Taylor N White 2004 International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis Lancet 363 9402 9 17 1:STN:280:DC%2BD2c%2FisF2mtg%3D%3D 10.1016/S0140-6736(03)15162-8 14723987 (Pubitemid 38076919)
29. WM Liu 2008 Enhancing the cytotoxic activity of novel targeted therapies-is there a role for a combinatorial approach? Curr Clin Pharmacol 3 2 108 117 1:CAS:528:DC%2BD1cXpvVGntrw%3D 10.2174/157488408784293714 18690885 Review
30. UK Laemmli 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 5259 680 685 1:CAS:528: DC%2BD3MXlsFags7s%3D 10.1038/227680a0 5432063
31. WM Liu KA Scott J Shamash S Joel TB Powles 2008 Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach Leuk Lymphoma 49 9 1800 1809 1:CAS:528:DC%2BD1cXhtFant7vO 10.1080/10428190802239188 18608861
32. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 1:CAS:528:DyaL2cXktlaksLk%3D 10.1016/0065-2571(84)90007-4 6382953
33. KT Batty TM Davis LT Thu TQ Binh TK Anh KF Ilett 1996 Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria J Chromatogr Biomed Appl 677 345 350 10.1016/0378-4347(95)00428-9 (Pubitemid 26106005)
34. T Efferth A Sauerbrey A Olbrich E Gebhart P Rauch HO Weber JG Hengstler ME Halatsch M Volm KD Tew DD Ross JO Funk 2003 Molecular modes of action of artesunate in tumor cell lines Mol Pharmacol 64 382 394 1:CAS:528: DC%2BD3sXlvVCns7k%3D 10.1124/mol.64.2.382 12869643 (Pubitemid 36910002)
35. AC Beekman AR Barentsen HJ Woerdenbag UW Van N Pras AW Konings FS el-Feraly AM Galal HV Wikstrom 1997 Stereochemistry-dependent cytotoxicity of some artemisinin derivatives J Nat Prod 60 325 330 1:CAS:528:DyaK2sXisleqsLw%3D 10.1021/np9605495 9134741 (Pubitemid 27184905)
36. Y Li F Shan JM Wu GS Wu J Ding D Xiao WY Yang G Atassi S Leonce DH Caignard P Renard 2001 Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle Bioorg Med Chem Lett 11 5 8 10.1016/S0960-894X(00)00578- 3 11140731 (Pubitemid 32006112)
37. JA Willoughby Sr SN Sundar M Cheung AS Tin J Modiano GL Firestone 2009 Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression J Biol Chem 284 2203 2213 1:CAS:528:DC%2BD1MXlvFaqtQ%3D%3D 10.1074/jbc.M804491200 19017637
38. J Wu Y Feng D Xie X Li W Xiao D Tao J Qin J Hu K Gardner SI Judge QQ Li J Gong 2006 Unscheduled CDK1 activity in G1 phase of the cell cycle triggers apoptosis in X-irradiated lymphocytic leukemia cells Cell Mol Life Sci 63 21 2538 2545 1:CAS:528:DC%2BD28Xht1KhurzE 10.1007/s00018-006-6138-z 17013563 (Pubitemid 44722383)
39. PM O'Neill VE Barton SA Ward 2010 The molecular mechanism of action of artemisinin-the debate continues Molecules 15 3 1705 1721 10.3390/ molecules15031705 20336009
40. NP Singh HC Lai 2005 Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells Anticancer Res 25 4325 4331 1:CAS:528: DC%2BD2MXht12itL7M 16309236 (Pubitemid 41665224)
41. T Chen M Li R Zhang H Wang 2009 Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy J Cell Mol Med 13 1358 1370 1:CAS:528:DC%2BD1MXhtFCku7bE 10.1111/j.1582-4934.2008.00360.x 18466355
42. Zhou HJ, Zhang JL, Li A, Wang Z, Lou XE (2009) Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother Pharmacol
43. T Hata H Yamamoto CY Ngan M Koi A Takagi B Damdinsuren M Yasui Y Fujie T Matsuzaki H Hemmi X Xu K Kitani Y Seki I Takemasa M Ikeda M Sekimoto N Matsuura M Monden 2005 Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells Mol Cancer Ther 4 1585 1594 1:CAS:528:DC%2BD2MXhtFWhtLnJ 10.1158/1535-7163.MCT-05-0011 16227409 (Pubitemid 41556442)
44. C Tolis GJ Peters CG Ferreira HM Pinedo G Giaccone 1999 Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines Eur J Cancer 35 796 807 1:CAS:528:DyaK1MXjvFyisro%3D 10.1016/S0959-8049(98)00425-0 10505042 (Pubitemid 29258151)
45. L Escoubet-Lozach IL Lin K Jensen-Pergakes HA Brady AK Gandhi PH Schafer GW Muller PJ Worland KW Chan D Verhelle 2009 Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism Cancer Res 69 7347 7356 1:CAS:528: DC%2BD1MXhtFaku7rL 10.1158/0008-5472.CAN-08-4898 19738071
46. C Riganti S Doublier D Viarisio E Miraglia G Pescarmona D Ghigo A Bosia 2009 Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression Br J Pharmacol 156 1054 1066 1:CAS:528:DC%2BD1MXltFSmurg%3D 10.1111/j.1476-5381. 2009.00117.x 19298255